Thursday, June 19, 2014

Partnerships Asia Spotlight: Developments in Informed Consent for Improved Patient Outcomes

Yesterday, we looked at what needs to be included in the informed consent process so that patients fully understand what they're getting themselves into.  When it comes to informed consent in the developing nations of Asia, it's important to understand both the sites that are conducting clinical trials as well as the participants.  In an article at DDN News, they look at the informed consent process and the challenges it imposes in Asia.  As many of the developing countries already have challenges with resources - properly completing the informed consent process in a way that the patients also understand is difficult.

This September at Partnerships in Clinical Trials Asia, we have a panel of experts in the Asian region who will be calling to discuss this topic in depth in the panel discussion Asian Developments in Informed Consent for Improved Patient Outcomes.

Featured Session: Developments in Informed Consent for Improved Patient Outcomes

Featured Panelists: 
  • Bhaswat Chakraborty, Senior Vice President & Chair Scientific Committee,
  • Cadila Pharmaceuticals, India
  • Carlos Linn, Asia-Pacific Regional Medical Director, Diversified Products, Pfizer, China
  • Joan Shen, Chief Medical Officer, Jiangsu Hengrui Medicine, China
  • Henry Yau, Managing Director, Clinical Trials Centre, The University of Hong Kong, Hong Kong
In this session, the panelists will discuss:
• Assessing the best strategy in obtaining informed consent
• Considering language and culture differences and the associated translation requirements
• Embracing new technologies to streamline the informed consent process

Partnerships in Clinical Trials Asia will take place September 16-18 in Shanghai, China. As a reader of this blog, when you register to join us and mention code XP1975BLOG, you'll save 15% off the standard rate.

No comments: